key: cord-0798276-4tx6r105
authors: Öhman, Fredrik; Hassenstab, Jason; Berron, David; Schöll, Michael; Papp, Kathryn V.
title: Current advances in digital cognitive assessment for preclinical Alzheimer's disease
date: 2021-07-20
journal: Alzheimers Dement (Amst)
DOI: 10.1002/dad2.12217
sha: db079149d2d5f9b141e8cb60828c6c9c47e11330
doc_id: 798276
cord_uid: 4tx6r105

There is a pressing need to capture and track subtle cognitive change at the preclinical stage of Alzheimer's disease (AD) rapidly, cost‐effectively, and with high sensitivity. Concurrently, the landscape of digital cognitive assessment is rapidly evolving as technology advances, older adult tech‐adoption increases, and external events (i.e., COVID‐19) necessitate remote digital assessment. Here, we provide a snapshot review of the current state of digital cognitive assessment for preclinical AD including different device platforms/assessment approaches, levels of validation, and implementation challenges. We focus on articles, grants, and recent conference proceedings specifically querying the relationship between digital cognitive assessments and established biomarkers for preclinical AD (e.g., amyloid beta and tau) in clinically normal (CN) individuals. Several digital assessments were identified across platforms (e.g., digital pens, smartphones). Digital assessments varied by intended setting (e.g., remote vs. in‐clinic), level of supervision (e.g., self vs. supervised), and device origin (personal vs. study‐provided). At least 11 publications characterize digital cognitive assessment against AD biomarkers among CN. First available data demonstrate promising validity of this approach against both conventional assessment methods (moderate to large effect sizes) and relevant biomarkers (predominantly weak to moderate effect sizes). We discuss levels of validation and issues relating to usability, data quality, data protection, and attrition. While still in its infancy, digital cognitive assessment, especially when administered remotely, will undoubtedly play a major future role in screening for and tracking preclinical AD.

In Alzheimer's disease (AD), the major pathophysiological processes (accumulation of amyloid beta protein [Aβ] into plaques assumed to be followed by the aggregation of hyperphosphorylated tau protein [ptau]into neurofibrillary tangles [NFT] ), begin years to decades prior to the clinical dementia syndrome. 1 During this preclinical phase, cognitive functions are largely unaffected, 2 but as neuropathological burden increases over time, subtle cognitive decrements emerge. 3 The preclinical phase offers a promising window for preventing decline, which emphasizes that capturing the subtle changes in cognition during this phase is immensely important. 4

In clinically normal (CN) individuals, abnormal levels of Aβ (Aβ+), as measured in cerebrospinal fluid (CSF) (e.g., levels of Aβ 42 or Aβ 42/40 ) or with positron emission tomography (PET) neuroimaging, are considered indicative of an early AD pathological process. 2, 3 During this preclinical stage of the disease continuum, the cross-sectional association between Aβ and cognitive deficits is generally weak, 5-8 or insignificant. [9] [10] [11] However, CN individuals with higher Aβ burden (Aβ+) exhibit faster cognitive decline, [12] [13] [14] and often progress to a clinical stage faster than those with lower levels of Aβ. [15] [16] [17] [18] This cognitive decline is subtle and detectable only over several years. In one study, Aβ+ CN participants declined at an average rate of −0.42 zscore units per 18 months, 19 while another study showed a decline of between -0.07 and -0.15 average z-score units per year. 20 The strongest association between AD biomarkers and cognitive decline is for memory function, 21 but there are also reports of decline across other cognitive domains, 22, 23 including executive 24 and visuospatial functions. 25 The second major pathogenic process in preclinical AD is tau aggregation into NFT, also measurable in CSF (e.g., p-tau) and with PET neuroimaging. 1 Compared to Aβ, tau has been considered more closely linked to cognitive impairment during the AD process. [26] [27] [28] In CN individuals, tau burden has been associated with memory impairment and longitudinal cognitive decline. 16, 29, 30 Given that tau PET is still relatively newer than Aβ PET, less is known about the longitudinal relation between tau and cognition, including later clinical progression. Generally, those with higher tau are at greater risk for longitudinal cognitive decline; importantly, however, this decline is several fold faster in Aβ+ CN individuals. [30] [31] [32] 

The relationship between paper-and-pencil measures of cognition and AD biomarkers among CN older adults is complex, but observed correlations are generally relatively weak, particularly cross-sectionally. 8 Longitudinally, these relationships are more consistently observed and of greater magnitude, with CN older adults with elevated biomarker levels exhibiting cognitive decline. 31, 33 Weak relationships between cognition and AD biomarkers may be partially attributable to the limitations of paper-and-pencil assessments, most of which were designed to detect frank impairment in clinical populations as opposed to being designed to detect subtle preclinical impairment. 34 Furthermore, normal fluctuations in cognitive performance, 35 practice effects, 36 and cognitive reserve 37 may obscure the detection of subtle cognitive decline.

The use of digital technology to assess cognition has the potential to mitigate some of the limitations of current paper-andpencil assessments. 38 For example, mobile devices enable more frequent testing, resulting in more reliable and informative longitudinal data 39 and are more accessible and cost-effective thanks to selfadministration. 40 Computerized measures that automatically generate alternative forms may help minimize practice and version effects. 41 Artificial intelligence (AI) methods such as deep learning enable faster, novel, and potentially more sensitive analysis of cognitive data. 42 Digital assessments also pose new challenges. Many studies using remote assessments struggle to maintain participant engagement. 43 Digital storage and sharing of cognitive data pose questions related to data privacy, 44 particularly when devices may collect additional identifiable personal data (e.g., voice recordings). Unsupervised digital assessments require systems to ensure the individual assigned to a remote assessment is the individual taking that assessment. Rapidly developing technologies and operating systems pose challenges to selecting and maintaining a single version of a digital assessment over time. Finally, while secular trends suggest that older adults are increasingly familiar and comfortable with new technology, 45 a not insignificant population may be excluded from research with digital assessments due to lack of familiarity, technical skills, or access.

Digital technology has not yet replaced paper-and-pencil assessments, particularly not in clinical trials, because multiple questions HIGHLIGHTS • Digital assessments for preclinical Alzheimer's disease (AD) vary by intended setting (e.g., remote vs. in-clinic), level of supervision (e.g., self vs. supervised), and device origin (personal vs. study-provided).

• At least 11 articles characterize digital cognitive assessment in biomarker-defined preclinical AD, but the literature generally remains nascent, particularly for remote and novel assessments.

• Multiple digital assessment instruments exhibit predominantly weak to moderate relationships with AD biomarkers in preclinical groups. More work is needed to confirm the concrete diagnostic potential in preclinical disease stages.

• Potential benefits and challenges are discussed within the framework of future implementation in clinical trials, including recommendations for future studies.

remain unanswered: Does digital technology capture cognitive information analogous to gold-standard paper-and-pencil measures? Is there a fundamental difference between capturing data with a rater versus a device? How reliable and feasible is digital technology? These questions are just beginning to be addressed in a more widespread fashion as use of digital technology is rapidly evolving, 46 for instance, in research on preclinical AD.

In this context, our objectives were to systematically review the current landscape of digital cognitive tests for use in preclinical AD and to describe the extent of validation of these digital cognitive tests against (1) gold-standard cognitive tests and test composites (paperand-pencil measures) and (2) biomarkers of Aβ and tau pathology. Furthermore, we will critically discuss the potential and pitfalls of digital cognitive assessments in the context of implementation in clinical trials, and to provide an outlook for the future of digital cognitive assessment. Our goal, however, was not to give an exhaustive overview of mobile technology 40 or computer testing 47 for use in elderly populations in general. Additionally, we do not address the separate field of passive monitoring to infer cognition using sensors and wearables. 48 We first describe the current understanding of the associations between cognitive performance on conventional paper-and-pencil measures and AD biomarkers. Subsequently, we discuss digital assessments organized into three groups based on technological platform and/or setting: (1) primarily in-clinic computerized and tablet-based, (e.g., digital pen, eye-tracking, and language analysis; novel methods for data analysis, e.g., using AI approaches).

For each digital assessment, validation is discussed in terms of (1) biomarker validation and (2) paper-and-pencil validation. 

A total of 469 articles were screened using the web-app Rayyan, 49 of which 458 were excluded due to failure to meet inclusion criteria, and 11 were included in the review. Grant applications were screened from the NIH research portfolio, but no additional study was included.

Since this initial literature search, two additional newly published articles were included. Preliminary results from seven conference presentations have also been included, specifically from CTAD 2020 and AAIC 2020. The resulting relatively small, heterogeneous, and methodologically inconsistent body of literature limited our review's methodology.

Therefore, we performed a qualitative synthesis rather than a metaanalysis. A number of computerized cognitive tests have been developed to detect cognitive decline. These may include stand-alone apps and programs as well as web-based apps that can be completed either on personal computers (PC) or tablets. Some of these tests consist of digitized versions of traditional paper-and-pencil neuropsychological tests, while others involve newly developed tests designed to be completed without the active participation or presence of an examiner; these include, for example, Savonix, BrainCheck, Cogniciti, Mindmore, BAC, NIH-Toolbox, CANTAB, and Cogstate, among others. Each vary in their approach, degree of commercialization, security and regulatory readiness, and degree of "gamification." They also differ in their respective target populations and clinical indications. Here, we focus on the systems and platforms specifically or mainly designed to detect the earliest cognitive decline in AD. See Table 1 for an overview of the validation of these types of cognitive assessment instruments. In Figure 1 Researchers from the Mayo Clinic Study on Aging used similar methods in a population-based sample, and in contrast, they did not find any significant association between Aβ and CBB decline. 59 In another study from AIBL, performance on a continuous paired associative learning task (CPAL) within the Cogstate battery was explored for Aβ+ and Aβ-CN. Over 36 months, Aβ-task performance improved over time,

whereas Aβ+ showed no practice effect. In CN, the absence of benefit from repeated exposure over time was associated with a higher Aβ burden. 60 3.1. 

There are a handful of studies examining NIH TB-CB in aging and dementia populations; however, there is currently a limited number of published studies on NIH TB-CB and preclinical AD biomarkers. A recent study in 118 CN older adults did not find an association between AD neuroimaging markers of Aβ and any of the NIH TB-CB cognitive tasks. However, they did find a weak association between measures of processing speed and executive functions and higher Braak regions of tau pathology. 63 

The Cambridge Neuropsychological Test Automated Battery (CANTAB)

The Cambridge Neuropsychological Test Automated Battery (CANTAB) is intended as a language-independent and culturally neutral cognitive assessment tool initially developed by the University of Cambridge in the 1980s, but now commercially provided by the company Cambridge Cognition. CANTAB has been used in a wide range of clinical settings and clinical trials, 64 including aging studies. 65 CANTAB mostly uses non-verbal stimuli, and it includes measures of working memory, planning, attention, and visual episodic memory.

Administration of CANTAB was initially on PC but is now available through CANTAB mobile (tablet-based). Additionally, CANTAB offers an online platform for recruitment by pre-screening patients using their cognitive assessment instruments.

In the Dallas Lifespan Brain Study, CN individuals underwent Aβ PET with [ 18 F]florbetapir) and the CANTAB Verbal Recognition Test, including measures of memory recall and recognition. In this test, the participants are shown a sequence of words on a touchscreen. Subsequently, the participant is asked to recall the words, and the task ends with a recognition task. The researchers found that in relatively younger adults (30 to 55), higher Aβ was moderately associated with diminished memory recall and recognition, whereas the effect weakened as people aged and amyloid levels increased. 66 

Demographic survey trends in the United States from 2019 indicated that 77% of Americans aged 50+ own smartphones 67 with that number climbing annually. 68 Similar numbers are being reported from European countries. 69 Simultaneously, there has been an increase in smartphone-based apps designed for cognitive assessment in older populations. 40 The appeal and implication of smartphone-based cognitive assessment for detection and tracking in preclinical AD are obvious. It is highly scalable, allowing for remote assessment in a much larger population compared to samples acquired through in-clinic and supervised assessment. It allows for more frequent assessment with potentially more sensitive cognitive paradigms. 70 With mobile technology, cognitive assessment can be performed in a familiar environment and may thus increase the ecological validity (i.e., the generalizability to real-life setting) of the task. Having a participant complete tasks on their own phone (as opposed to a study-issued device) may be more reflective of their cognition in everyday life. Improved ecological validity of smartphone-based assessment is timely, as researchers and regulators emphasize the importance of demonstrating the clinical meaningfulness of cognitive change in a preclinical AD population. Furthermore, the participant being in a familiar environment during cognitive assessments may reduce the risk of the "white-coat effect" (participants underperforming on tasks in a medical environment). 71 Remote and mobile tracking of cognitive functioning provide an extra opportunity for an individual to track their own cognitive health over time, potentially leading to increased commitment to their well-being. 72 Finally, for those willing to participate in demanding clinical trials, reducing in-clinic visits through remote testing may mitigate the overall participant burden and encourage those in more remote areas to participate.

However, despite the potential of smartphone-based assessment, multiple issues remain, including challenges related to (1) feasibility (e.g., older adults' openness to completing smartphone assessments, compliance, attrition, privacy issues), (2) validity (e.g., ensuring alignment between smartphone-based vs. gold standard cognitive assessment data, guaranteeing the identity of the examinee), and (3) reliability (e.g., variability between hardware and operating systems, diminished control over the test-taking environment).

Given the recent rapid expansion of interest in this area, we focus on observed themes for smartphone-based instruments that are in early (but varying) stages of development. Identified themes include (1) improving reliability of assessment through ambulatory/momentary testing, (2) using mobile and serial assessment to identify subtle decrements in learning and practice effects, (3) targeting cognitive processes more specific to decline in preclinical AD, (4) and harnessing the potential of big-data collection. Validity data in relation to in-clinic cognitive assessment and AD biomarkers is discussed where available. Table 2 displays the validation of remotely administered tablet-and smartphone-based cognitive assessments.

Feasibility of using mobile devices to capture cognitive function While retention in longitudinal study designs is especially challenging for studies using remotely administered testing, adherence in short studies is promising. In a recent study, 1594 CN subjects (age = 40 to 65) completed a testing session using a web-based version of four playing card tasks within the Cogstate battery. 53 High adherence to instructions and low rates of missing data were observed (1.9%), indicating high acceptability. Error rates were consistently low across tests and did not vary due to the self-reported environment (e.g., with others present or in a public space). Another recent study investigated adherence during 36 days using a smartphone-based app. 73 Thirty-five CN participants (age = 40 to 59) completed very short daily cognitive tasks, where 80% completed all tasks, with 88% of the participants still active at the end of the study. More problematic, a recent report from eight digital health studies (providing study-app usage data from > 100,000 participants) in the United States describes substantial participant attrition (e.g., participants losing engagement over time), confounding the generalizability of data obtained. 43 Monetary compensation improved retention, and boding well for preclinical AD studies, older age was associated with longer study participation duration. However, participants involved in trials that included in-clinic visits had the highest compliance, suggesting that attrition in fully remote longitudinal studies remains a significant challenge.

Improving reliability: ambulatory/momentary cognitive assessment

The premise behind ambulatory/momentary cognitive assessment is that single-timepoint assessments fail to capture the endemic variability in human cognitive performance impacted by a host of factors, including mood, stress, or time of day. 35 Capturing the most representative sample of an individual's cognition at a given interval is one promising approach to improving the sensitivity of measurement by reducing variability and increasing reliability. Using a "burst" design, a TA B L E 2 Validation of remotely administered tablet-and smartphone-based cognitive assessment and other novel types of cognitive assessment Further work is required to determine whether ambulatory cognitive data are (1) more strongly related to AD-biomarker burden in CN older adults compared to conventional in-clinic assessments and (2) whether these data represent a more reliable measure of cognitive and clinical progression compared to conventional in-clinic assessments.

Using mobile and serial assessment to identify subtle decrements in learning and practice effects A diminished practice effect, that is, a lack of the characteristic improved performance on retesting, has been suggested as a subtle indicator of cognitive change prior to overt decline. 76 Mobile technology allows for much more frequent serial assessment. For example, a recent study provided iPads to 94 participants to take home and to complete a monthly challenging associative memory task requiring memory for face-name pairs (FNAME) for 1 year. 77 They found an association between diminished learning and greater amyloid and tau PET burden among CN, with the Aβ ± group differences in memory performance emerging by the fourth exposure.

Work using a web-based version of FNAME 78 and other memory tasks, called the Boston Remote Assessment for Neurocognitive Health (BRANCH), was designed to move learning paradigms from study-provided tablets to smartphones and to reduce the time interval for serial assessment (e.g., from months to days). These tasks focus on cognitive processes supported by the medial temporal lobes and thus best able to characterize AD-related memory changes. BRANCH primarily consists of measures of associative memory, pattern sepa-ration, and semantically facilitated learning and recall. BRANCH also uses paradigms and stimuli relevant to everyday cognitive tasks. 79 In a similar vein, the Online Repeatable Cognitive Assessment-

University in Australia, asks participants to learn the English word equivalents of 50 Chinese characters for 25 minutes daily over 6 days.

The task is web-based and completed on a participant's own device in their home. They found that learning curves were diminished in 38 Aβ+ versus 42 Aβ-CN older adults, and the magnitude of this difference was very large. 80 The assessment of learning curves over short time intervals using smartphones may serve as a cost-effective screening tool to enrich samples for AD biomarker positivity prior to expensive assays. For example, a clinical study found that lower practice effects over 1 week were associated with a nearly 14 times higher odds of being Aβ+ on a composite measure using [ 18 F]flutemetamol. 81 Future work with larger CN samples and further optimized learning paradigms may show similar discriminability properties of learning curves to AD biomarker positivity in a preclinical sample. Capturing learning curves over short intervals using remote smartphone-based assessment may provide a more rapid means of assessing whether a novel treatment has beneficial effects on cognition. This could assist in more rapidly discontinuing futile treatment trials or, more importantly, trials with deleterious effects on cognition. 82 However, how the repeated measures of short-term learning curves can be used to track cognitive progression remains unexplored. Methods to establish this relationship are in development but will require validation studies to overcome logistical and technical challenges.

While there is significant heterogeneity in the nature and progression of cognitive decline within AD, the availability of AD biomarkers and adoption of findings from the cognitive neuroscience literature have allowed researchers to hone in on cognitive processes potentially more sensitive and specific to AD. For example, researchers from the Otto-von-Guericke University in Magdeburg and the German Center for Neurodegenerative Diseases (DZNE) have been involved in the development of a digital platform including a mobile app for smartphones and tablets (neotiv), which consists of memory tests focused on object and scene mnemonic discrimination, 83 pattern completion, 84 face-name association, 85 and complex scene recognition. 86 The object and scene mnemonic discrimination paradigm was designed to capture memory function associated with an object-based (anterior-temporal) and a spatial (posterior-medial) memory system. 87 While functional magnetic resonance imaging (fMRI) studies have shown that both memory systems were activated in individuals performing the task, age-related and performance-dependent changes in functional activity have been observed in the anterior temporal lobe in older adults. 83 Furthermore, two studies in biomarker-characterized individuals revealed that object mnemonic discrimination performance was associated with measures of tau pathology (i.e., anterior temporal tau-PET binding and CSF p-tau levels), while there was evidence for an association of performance in the scene mnemonic discrimination task with Aβ-PET signal in posterior-medial brain regions. 88, 89 The complex scene recognition task has been shown to rely on a wider episodic memory network 86 and task performance was associated with CSF total-tau levels. 90 93 The neotiv platform is currently included in several AD cohort studies (e.g., DELCODE, BioFINDER-2, and WRAP).

Harnessing the potential of "big data": citizen science projects Citizen science is a concept in which the general public is involved in collaborative projects, for example, by collecting their own data for use in research, 94 and can be a way to gather large amounts of data on individuals at risk of developing AD. One such citizen science project is The Many Brains Project, with their research platform TestMyBrain.org. 95 The Many Brains Project has yielded some of the largest samples in cognition research, with more than 2.5 million people tested since 2008; however, the study is not specific to AD. Another study, the Models of Patient Engagement for Alzheimer's Disease study, is an EUfunded international initiative aiming to identify individuals with early AD hidden in their communities and traditionally not found in memory clinic settings. 96 

Other promising assessment instruments under evaluation in different studies on preclinical AD are the analyses of spoken language, eye movements, spatial navigation performance, and digital pen stroke data. Some of these tasks require stand-alone equipment (e.g., eyetracker, digital pen), while others can use existing platforms or devices (e.g., device-embedded cameras, 98 such as those in a personal laptop or the front-facing camera on a smartphone). Figure 3 exemplifies some of these assessment instruments. Table 2 displays the validation of novel types of assessment instruments. Some instruments, such as commercial-grade eye-tracking cameras, or digital pens, are still not widely accessible, hampering their implementation. Predominantly passive monitoring of cognition, such as speech recording and eye movement-tracking, may prove less stressful and time-consuming than conventional cognitive tests. Participants complete a task of objective cognition (e.g., drawing a clock, or describing a picture) while subtle aspects of their performance are being recorded (e.g., pen strokes, eye movements, language). The result is a large quantity of data about performance, which must then be reduced or synthesized to glean relevant performance features. Using machine learning (ML) or deep learning, researchers have started to investigate whether automated analyses and classification of test performance according to specific criteria (e.g., biomarker or clinical status) can aid in sensitive screening in preclinical AD. 99, 100 In a clinical context, ML can be used as a clinical decision support system, building prediction models that achieve high accuracy in clinical diagnosis and selecting patients for clinical trials at the early stages of dementia development. 101, 102 3.3.1

Spoken language analysis and automated language processing New technical developments have provided further insight into language deficits in preclinical AD, and several newly developed analysis F I G U R E 3 A, Sea Hero Quest Wayfinding and Path integration. Used with permission from M. Hornberger. B, Digital Maze Test from survey perspective and landmarks from a first-person perspective. Used with permission from D. Head. C, Data and analysis process for digital Clock Drawing Test (dCDT), from data collection, the artificial intelligence (AI) analysis steps, and the machine learning (ML) analysis and reporting. Used with permission from Digital Cognition Technologies instruments are now available. 103 For these instruments, speech production is usually recorded during spontaneous speech; verbal fluency tasks; or describing a picture, typically using the Cookie Theft picture from the Boston Diagnostic Aphasia Examination. 104 Speech is typically recorded using either a stand-alone audio recorder or embedded microphone, and after that, transcribed and analyzed using computer software. For example, using a picture task, researchers can analyze speech, such as verbs and nouns in spontaneous speech; the complexity of sentences, as represented by grammatical complexity and verb usage; diversity of words; and the flow of speaking, such as speech repetitions and pauses. 105 Transcription of speech to text, a vital part of speech analysis, is by definition time consuming, but there has been an increasing effort to apply machine-and deep-learning technology to detect cognitive impairment in AD. For example, researchers from the European research project Dem@care and the EIT Digital project ELEMENT demonstrated that automated analysis of verbal fluency could distinguish between healthy aging and clinical AD, 106 as well as vocal analysis using smartphone apps for automatic differentiation between different clinical AD groups. 107 In the latter, speech was recorded while performing short verbal cognitive tasks, including verbal fluency, picture description, counting down, and a free speech task. Thereafter, it was used to train automatic classifiers for detecting MCI and AD, based on ML methods. The question is still whether they can identify early cognitive impairment and decline in preclinical AD.

Intensive development of these methods is ongoing at sev- 

While most researchers have investigated MCI patients, 108 researchers from the Netherlands-based Subjective Cognitive Impairment Cohort recorded spontaneous speech in CN individuals performing three open-ended tasks (e.g., describing an abstract painting). After manual transcription, the researchers extracted linguistic parameters using a fully automated freely available software (T-Scan).

Using conventional neuropsychological tests, the participants performed within normal range, regardless of Aβ status (either using CSF Aβ1-42 or [ 18 F]florbetapir-PET). Interestingly, a modest correlation was seen between abnormal Aβ and subtle speech changes (fewer specific words). 109 

In AD research, commercial-grade eye-tracking cameras have been shown to detect abnormal eye movements in clinical groups. 110, 111 These are high frame rate cameras managing to collect a wealth of data on eye movement behavior, including saccades (simultaneous eye movements), and fixation (eyes focusing on areas 

In this systematic review, several digital assessments were identified on multiple delivery platforms (e.g., tablets, smartphones, and external hardware), intended to measure cognition or behaviors in preclinical AD (see Figure 4 for an overview of assessments and their platforms). These assessment instruments varied by intended setting (e.g., remote vs. in-clinic), level of supervision (e.g., self vs. supervised), and device origin (personal vs. study-provided). Studies validating assessment instruments for more established platforms (e.g., PC, tablet) are more common than those developed for more novel platforms (e.g., smartphone). However, many of these newly developed tests are currently being evaluated in several biomarker studies. 

In addition to validation using preclinical AD biomarkers, an alternative means of validation is to compare digital assessments against conventional cognitive measures used in large-scale studies. This type of validation can supplement biomarker studies or provide important preliminary data before using more costly biomarker studies. A handful of assessment instruments, including a tablet-based test, 58 eye-tracking assessment, 112 and a smartphone app, 92 have been validated against relevant global cognitive composites, indicating some validity for further study of biomarkers in preclinical AD. However, as the correlation between conventional composites and preclinical AD is already weak, pen-and-paper validation alone is not enough to be able to claim that a test is suitable as a measure of subtle cognitive changes in preclinical AD. The different digital assessment instruments discussed in this review enable different usage. Supervised digital assessment instruments could provide robust outcomes in clinical trials, with benefits such as automatic recording of response and scoring, making it easier to follow study protocols, reducing the risk of error, and increasing inter-rater reliability. Remotely administered tests could serve as a cost-effective pre-screening before more expensive and invasive examinations, such as lumbar puncture and brain imaging, are recommended. In clinical trials, mobile devices could be used to identify individuals at greatest risk of cognitive decline, who are most likely to benefit from a specific intervention. Close follow-up of people's cognitive function from their home environment may also enable high-quality evaluation of interventions.

Importance of data security, privacy, and adherence

As an effect of the increasingly digitized cognitive testing, the issue of data security and privacy issues have been raised by regulatory authorities. Pharmaceutical companies have also emphasized the importance of these issues. One such consideration is the data storage and transmission between servers, crucial when data are to be stored and processed on servers that are not under the direct control of the study.

When commercial companies are involved, questions can arise regarding ownership of data and conflicts of interest.

Data protection in the United States is governed by several laws enacted on federal and state levels (e.g., Patient Safety and Quality Improvement Act and Health Information Technology for Economic and Clinical Health Act). In the European Union (EU), the General Data Protection Regulation (GDPR) governs data storage and processing in EU countries. It affects scientific cooperation between countries inside and outside the EU. Technological development places increased demands on developers and researchers to familiarize themselves with regulatory issues, especially now that new types of personal data are gathered to a greater extent and across country borders.

Finally, an important and necessary focus is to ensure that data captured remotely, in an uncontrolled environment, is reliable and an accurate reflection of an individual's cognitive functioning. Here also the importance of adherence comes into play and, although there is increasing evidence that unsupervised testing can be done, large longitudinal health studies also indicate that there are significant problems with participant attrition. Work remains to ensure valid and reliable results for participants performing unsupervised testing in large clinical trials.

This review highlights the wealth of digital assessment instruments currently being evaluated in preclinical populations. Digital technology can be used to assess the subtle cognitive decline that defines biomarker-confirmed preclinical AD. Potential benefits include increased sensitivity and reliability, and it could add value to individuals through increased accessibility, engagement, and reduced participant burden. Digital assessments may have clinical trial implications by optimized screening, facilitating case finding, and providing more sensitive clinical outcomes. Several promising tests are currently in development and are undergoing validation, but work remains before many of these can be considered alongside conventional in-clinic cognitive assessments. We have begun to understand the reliability and validity of cognitive assessments obtained in naturalistic environments, which is required before beginning cognitive testing outside research centers on a large scale. Last, more feasibility studies investigating potential barriers for implementation are needed, including the challenges of adherence, privacy, and data security. 

Biomarker modeling of alzheimer's disease

NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimer's Dement

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement

Measuring cognition and function in the preclinical stage of Alzheimer's disease. Alzheimer's Dement

Subjective cognition and amyloid deposition imaging: a Pittsburgh compound B positron emission tomography study in normal elderly individuals

Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals

The computerized cognitive composite (C3) in A4, an Alzheimer's disease secondary prevention trial

Detectable neuropsychological differences in early preclinical Alzheimer's disease: a meta-analysis

Frequent amyloid deposition without significant cognitive impairment among the elderly

Cognitive consequences of high aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease

Brain amyloid-β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly

Amyloid β-Associated cognitive decline in the absence of clinical disease progression and systemic illness

Relationships between performance on the cogstate brief battery, neurodegeneration, and aβ accumulation in cognitively normal older adults and adults with MCI

Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5. Alzheimer's Dement

Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing

Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

Cued memory decline in biomarker-defined preclinical Alzheimer disease

Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimer's Dement

Meta-analysis of amyloidcognition relations in cognitively normal older adults

Detecting cognitive changes in preclinical Alzheimer's disease: a review of its feasibility

Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: a meta-analysis. Alzheimer's Dement

Association of elevated amyloid levels with cognition and biomarkers in cognitively normal people from the community

Longitudinal study of the transition from healthy aging to Alzheimer disease

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature

Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease

Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease

Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging

PET imaging of tau deposition in the aging human brain

Does early cognitive decline require the presence of both tau and amyloid-β?

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age

Amyloid accumulation and cognitive decline in clinically normal older individuals: implications for aging and early Alzheimer's disease

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review

Measurement-burst designs for social health research

Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer's disease randomized controlled trials

Evaluating cognitive reserve through the prism of preclinical Alzheimer disease

Applications of computer-based neuropsychological assessment

Reliability and validity of ambulatory cognitive assessments

Mobile technology for cognitive assessment of older adults: a scoping review

The technology crisis in neuropsychology

Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimer's Dement

Indicators of retention in remote digital health studies: a cross-study evaluation of 100,000 participants

A Casebook of Ethical Challenges in Neuropsychology

PI_2017.05.17_Older-Americans-Tech_FINAL

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Status of computerized cognitive testing in aging: a systematic review

Digital biomarkers for Alzheimer's disease: the mobile/wearable devices opportunity. npj Digit Med

Rayyan-a web and mobile app for systematic reviews

Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex

Intraindividual cognitive decline using a brief computerized cognitive screening test

Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies

Unsupervised assessment of cognition in the healthy brain project: implications for web-based registries of individuals at risk for Alzheimer's disease. Alzheimer's Dement

Development of a psychometrically equivalent short form of the face-name associative memory exam for use along the early Alzheimers disease trajectory

A task to assess behavioral pattern separation (BPS) in humans

Age and amyloid-related alterations in default network habituation to stimulus repetition

Overcoming interference: an fMRI investigation of pattern separation in the medial temporal lobe

Computerized cognitive testing for use in clinical trials: a comparison of the NIH toolbox and CogState C3 batteries

Influence of amyloid and APOE on cognitive performance in a late middle-aged cohort

Visual paired associate learning deficits associated with elevated beta-amyloid in cognitively normal older adults

NIH Blueprint for Neuroscience Research. The NIH toolbox: setting a standard for biomedical research

Cognition assessment using the NIH Toolbox

Associations between NIH toolbox cognition battery and in vivo brain amyloid and tau pathology in nondemented older adults

Neuorpsychiatyric applications of CANTAB

Do the Cambridge neuropsychological test automated battery episodic memory measures discriminate amnestic mild cognitive impairment?

Amyloid deposition in younger adults is linked to episodic memory performance

Tech Trends of the 50+: Infographic

Mobile Fact Sheet. Pew Research Center: Mobile Fact Sheet

Nuremberg Institute for Market Decisions. Consumer Study

P1-466: diminished practice effects on a monthly computerized and home-administered face-name associative memory exam are predictive of elevated pet amyloid in normal older adults

Is medical environment detrimental to memory? A test of a white coat effect on older people's memory performance

Direct release of test results to patients increases patient engagement and utilization of care

Evaluating the feasibility of frequent cognitive assessment using the Mezurio smartphone app: observational and interview study in adults with elevated dementia risk

Presentation: Remote Assessment Approaches in the Dominantly Inherited Alzheimer Network (DIAN). In: Alzheimer's Association International Conference

Feasibility and validity of mobile cognitive testing in the investigation of age-related cognitive decline

Absence of practice effects in preclinical Alzheimer's disease. Neuropsychology

Diminished Learning Over Repeated Exposures (LORE) in preclinical Alzheimer's disease. Alzheimer's Dement

Face-name associative memory performance is related to amyloid burden in normal elderly

Presentation: Repeated Memory-Based Assessments: Implications for Clinical Trials and Practice

Association of deficits in short-term learning and Aβ and hippoampal volume in cognitively normal adults

Short-term practice effects and amyloid deposition: providing information above and beyond baseline cognition

Randomized trial of verubecestat for prodromal Alzheimer's disease

Age-related functional changes in domain-specific medial temporal lobe pathways

Holistic recollection via pattern completion involves hippocampal subfield CA3

Face-name associative recognition deficits in subjective cognitive decline and mild cognitive impairment

Functional phenotyping of successful aging in long-term memory: preserved performance in the absence of neural compensation

Two cortical systems for memory-guided behaviour

Alzheimer's pathology targets distinct memory networks in the ageing brain

Higher CSF tau levels are related to hippocampal hyperactivity and object mnemonic discrimination in older adults

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume

Presentation: Remote Mobile App-Based Memory Assessments Reflect Traditional Memory Measures and are Sensitive to Measures of Tau Pathology

Presentation: Remote Smartphone-Based and Supervised Neuropsychological Assessments of Episodic Memory Recall are Highly Correlated

Age impairs mnemonic discrimination of objects more than scenes: a web-based, large scale approach across the lifespan

An analysis of citizen science based research: usage and publication patterns

Digital Cognitive Assessment: Results from the TestMyBrain NIMH Research Domain Criteria (RDoC) Field Test Battery Report

The MOPEAD project: advancing patient engagement for the detection of "hidden" undiagnosed cases of Alzheimer's disease in the community

Presentation: Fesibility of Mobile App-Based Assessment of Memory Functions-Insights from a Citizen Science Study

Scalable webcam eye tracking using user interactions

A machine learning approach to screen for preclinical Alzheimer's disease

Learning classification models of cognitive conditions from subtle behaviors in the digital Clock Drawing Test

The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's disease. Interface Focus

A practical computerized decision support system for predicting the severity of Alzheimer's disease of an individual. bioRxiv

Connected speech in neurodegenerative language disorders: a review

The Assessment of Aphasia and Related Disorders

Declines in connected language are associated with very early mild cognitive impairment: results from the Wisconsin Registry for Alzheimer's Prevention

Fully automatic speech-based analysis of the semantic verbal fluency task

Use of speech analyses within a mobile application for the assessment of cognitive impairment in elderly people

Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review

High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline

Saccade deficits in amnestic mild cognitive impairment resemble mild Alzheimer's disease

The potential utility of eye movements in the detection and characterization of everyday functional difficulties in mild cognitive impairment

Device-embedded cameras for eye tracking-based cognitive assessment: validation with paperpencil and computerized cognitive composites

Presentation: Capturing Cognitive Changes at the Earliest Stage of Alzheimer's Disease: A New Approach

Diagnostic differentiation of mild cognitive impairment due to Alzheimer's disease using a hippocampus-dependent test of spatial memory

Allocentric and egocentric spatial processing in middle-aged adults at high risk of late-onset Alzheimer's disease : the PREVENT Dementia Study

Differentiation of mild cognitive impairment using an entorhinal cortex-based test of virtual reality navigation

Virtual navigation tested on a mobile app is predictive of real-world wayfinding navigation performance

Toward personalized cognitive diagnostics of at-geneticrisk Alzheimer's disease

Spatial navigation in preclinical Alzheimer's disease

Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimer's Dement